Fig. 1From: Combination of GT90001 and nivolumab in patients with advanced hepatocellular carcinoma: a multicenter, single-arm, phase 1b/2 studyStudy profile. *No DLTs were observed in the 7.0 mg/kg cohort. RP2D = recommended phase 2 dose; DLTs = dose-limiting toxicitiesBack to article page